Controversial FDA Panel Approves Drug For Use By Children; New DNA Test Alerts Physicians And Parents To Potential Harm
An FDA advisory panel’s recommendation to allow Celebrex to be marketed for children suffering from juvenile rheumatoid arthritis (JRA) has some experts concerned over long-term health effects. While the issue of short-term efficacy and safety did not seem a big issue with the FDA panel, long term safety was a matter of concern. The disease affects some 60,000 children nationally. [click link for full article]